Found: 4
Select item for more details and to access through your institution.
Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 3, p. 180, doi. 10.1002/cpdd.234
- By:
- Publication type:
- Article
Mass balance, routes of excretion, and pharmacokinetics of investigational oral [<sup>14</sup>C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 666, doi. 10.1007/s10637-018-0693-7
- By:
- Publication type:
- Article
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [<sup>14</sup>C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 3, p. 407, doi. 10.1007/s10637-017-0509-1
- By:
- Publication type:
- Article
Biotransformation of [<sup>14</sup>C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces.
- Published in:
- 2018
- By:
- Publication type:
- journal article